Japanese companies were involved in 35 blockbuster products in fiscal 2025. Opdivo, developed by Ono Pharmaceutical, had the highest sales, while Kerendia and Alyftrek are among the candidates to become new blockbusters in fiscal 2026.
Of the blockbuster products in fiscal 2025, Japanese companies were involved in 35. The top products by global sales remained largely unchanged from the previous fiscal year.
The product with the highest sales was Opdivo, developed by Ono Pharmaceutical, which ranked 12th overall. Xtandi and Entyvio followed among the top-selling products.
Globally, Kerendia and Alyftrek are among the candidates to become new blockbusters in fiscal 2026.